Literature DB >> 15255090

Physician adherence to recommendations for duration of empiric antibiotic treatment for uncomplicated urinary tract infection in women: a national drug utilization analysis.

Natan R Kahan1, David P Chinitz, Ernesto Kahan.   

Abstract

BACKGROUND: Current guidelines for the empiric treatment of uncomplicated urinary tract infection in women recommend that first-line trimethoprim-sulfamethoxazole (TMP-SMX) or ofloxacin be given for 3 days and nitrofurantoin for 5 days. Increasing the duration of treatment raises costs, and perhaps, the incidence of adverse effects, without contributing to effectiveness. The aim of this study was to investigate physician adherence to these recommendations.
METHODS: The electronic patients record system of a nationwide health management organization in Israel was reviewed for all primary care visits by adult women treated empirically for cystitis or urinary tract infection from January 2001 to June 2002 (n = 7738 patient-physician encounters). The proportion of cases treated according to the guidelines, with regard to duration, was calculated for each drug used.
RESULTS: Rate of adherence was 3.36% for cases of TMP-SMX treatment (95%CI: 2.56%, 4.15%), 22.23% for nitrofurantoin (95%CI: 19.81%, 24.65%) and 4.08% for ofloxacin (95%CI: 2.88%, 5.28%). The crude rate of adherence for all cases of treatment with these drugs was 8.67% (95%CI: 7.82%, 9.52%).
CONCLUSIONS: The high rate of nonadherence observed (91.33%) indicate a need for a remedial education program for physicians to improve empiric treatment of urinary tract infection in women. Since this issue is of global importance, we believe our evaluation can serve as model for other settings and countries.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15255090     DOI: 10.1002/pds.862

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  7 in total

1.  U.S. public's experience with ticks and tick-borne diseases: Results from national HealthStyles surveys.

Authors:  Sarah A Hook; Christina A Nelson; Paul S Mead
Journal:  Ticks Tick Borne Dis       Date:  2015-04-15       Impact factor: 3.744

2.  When gatekeepers meet the sentinel: the impact of a prior authorization requirement for cefuroxime on the prescribing behaviour of community-based physicians.

Authors:  Natan R Kahan; David P Chinitz; Dan-Andrei Waitman; Ernesto Kahan
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

Review 3.  Contemporary management of uncomplicated urinary tract infections.

Authors:  David R P Guay
Journal:  Drugs       Date:  2008       Impact factor: 9.546

4.  Low Concordance With Guidelines for Treatment of Acute Cystitis in Primary Care.

Authors:  Larissa Grigoryan; Roger Zoorob; Haijun Wang; Barbara W Trautner
Journal:  Open Forum Infect Dis       Date:  2015-10-26       Impact factor: 3.835

5.  Symptomatic treatment (using NSAIDS) versus antibiotics in uncomplicated lower urinary tract infection: a meta-analysis and systematic review of randomized controlled trials.

Authors:  Albert Macaire C Ong Lopez; Charles Jeffrey L Tan; Antonio S Yabon; Armin N Masbang
Journal:  BMC Infect Dis       Date:  2021-06-29       Impact factor: 3.090

6.  Case-based audit and feedback around a decision aid improved antibiotic choice and duration for uncomplicated cystitis in primary care clinics.

Authors:  Larissa Grigoryan; Roger Zoorob; George Germanos; Mohamad Sidani; Matthew Horsfield; Fareed Khan; Mohammad Zare; Melanie Goebel; Robert Atmar; Barbara Trautner
Journal:  Fam Med Community Health       Date:  2021-07

7.  Relationship between the appropriateness of antibiotic treatment and clinical outcomes/medical costs of patients with community-acquired acute pyelonephritis: a multicenter prospective cohort study.

Authors:  Choseok Yoon; Se Yoon Park; Bongyoung Kim; Ki Tae Kwon; Seong-Yeol Ryu; Seong-Heon Wie; Hyun-Uk Jo; Jieun Kim; Kyung-Wook Hong; Hye In Kim; Hyun Ah Kim; Mi-Hee Kim; Mi-Hyun Bae; Yong-Hak Sohn; Jieun Kim; Yangsoon Lee; Hyunjoo Pai
Journal:  BMC Infect Dis       Date:  2022-02-01       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.